Results 121 to 130 of about 4,375,511 (236)

Toxicity Differences Between Microplastics and Nanoplastics in Organs: From Molecular Mechanisms to Potential Therapeutic Strategies

Med Research, EarlyView.
This review systematically compares the size‐dependent toxicity of microplastics and nanoplastics in the intestine, liver, kidney, lung, and brain. Particle size determines bioavailability, barrier penetration, and injury mechanisms. Because of their small size and high surface reactivity, NPs readily cross the intestinal epithelium and blood–brain ...
Yixian Cheng, Junjie Chen, Rui Fu, Jiawei Zhang, Jianguang Jia, Wei Wang, Zheng Zhang, Peng Zhang, Haosong Chen, Huake Cao, Gang Li, Weiwei Sheng, Ting Li, Bo Chen, Guodong Cao   +14 more
wiley   +1 more source

Recent Advances in Exosome‐Based Nanodelivery Systems for Traumatic Brain Injury Treatment

Med Research, EarlyView.
An overview of functional modification, therapeutic effects, molecular composition, and delivery strategies for exosomes. ABSTRACT Traumatic brain injury (TBI) is a highly heterogeneous neurological condition with extremely high rates of mortality and disability.
Jue Zhu, Weiquan Liao, Ziqi Lian, Mengdan Zhang, Chenxing Wang, Xingjia Zhu, Lin Zhang, Jian Chen, Zhichao Lu, Peipei Gong   +9 more
wiley   +1 more source

Lipid Challenge Reveals Amplified Apolipoprotein Responses with Preserved Temporal Pattern in Polyendocrine Metabolic Ovarian Syndrome: An Exploratory Study. [PDF]

Int J Mol Sci
Rajab E, Moin ASM, Nandakumar M, Sathyapalan T, Butler AE, Atkin SL.   +5 more
europepmc   +1 more source

Organoid Coculture Models for Cancer Research and Immunotherapy

Med Research, EarlyView.
This review summarizes organoid coculture platforms, including submerged Matrigel culture, air–liquid interface, microfluidic/organoid‐on‐a‐chip, and 3D bioprinting, for reconstructing the tumor microenvironment to study tumor–stroma/immune crosstalk, evaluate immunotherapies, and enable drug screening.
Zhuo Yang, Huihui Yang, Guangxin Li, Guobang Liu, Zhulan Chen, Wenzhi Tian, Meiyang Huang, Xiaoling Liu, Yongsheng Zhao, Dong Chen   +9 more
wiley   +1 more source

<i>Glycyrrhiza glabra</i> exhibits disease-modifying effects in Alzheimer's disease through restoration of mitochondrial function, synaptic plasticity, and kinase signaling. [PDF]

Front Pharmacol
Amrutha S, Kadandelu M, Paidi MK, Raghu SV, Prasad TSK, Modi PK.   +5 more
europepmc   +1 more source

Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression

Medicinal Research Reviews, EarlyView.
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu, Saurabh Upadhyay, Moustafa T. Gabr   +2 more
wiley   +1 more source

Astrocytoma-Specific Prognostic Associations of Amyloid-Related Biological Processes. [PDF]

Pathophysiology
Narvaez Irizarry FY, Porter TR, Ramirez Serrano N, Kucheryavykh LY.   +3 more
europepmc   +1 more source

Navigating the Complexity: A Comprehensive Review of GSK‐3 Inhibition in Regenerative Medicine

Medicinal Research Reviews, EarlyView.
ABSTRACT Glycogen synthase kinase‐3 (GSK‐3) is a central regulator of numerous cellular signaling pathways, with critical roles in metabolism, proliferation, differentiation, and tissue regeneration. This review explores the multifaceted effects of pharmacological GSK‐3 inhibition across multiple body districts, focusing on its highly context‐dependent
Davide Schiroli, Alessia Merra, Chiara Marraccini, Lucia Merolle, Graziella Pellegrini, Eleonora Maurizi   +5 more
wiley   +1 more source

The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective. [PDF]

Basic Clin Pharmacol Toxicol
Catakli D, Ozen-Basoglu O, Tuncgovde EB, Ozsarlak-Sozer G.   +3 more
europepmc   +1 more source

Artificial Intelligence‐Driven Natural Product Drug Discovery: From Computational Genome Mining to Clinical Translation

Medicinal Research Reviews, EarlyView.
ABSTRACT Natural products (NPs) have historically yielded numerous therapeutic agents, yet their integration into modern drug discovery has been constrained by chemical complexity, low abundance, laborious dereplication, and limited target annotation.
Antonio Lavecchia
wiley   +1 more source